| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.1 | $0-$5k | 0.00 |
Summary
A vulnerability labeled as critical has been found in Avast Antivirus up to 16. This vulnerability affects unknown code of the component Self-Defense. Executing a manipulation can lead to access control. This vulnerability is tracked as CVE-2017-8308. The attack is restricted to local execution. No exploit exists. The affected component should be upgraded.
Details
A vulnerability has been found in Avast Antivirus up to 16 (Anti-Malware Software) and classified as critical. This vulnerability affects an unknown part of the component Self-Defense. The manipulation with an unknown input leads to a access control vulnerability. The CWE definition for the vulnerability is CWE-264. As an impact it is known to affect confidentiality, integrity, and availability. CVE summarizes:
In Avast Antivirus before v17, an unprivileged user (and thus malware or a virus) can mark an arbitrary process as Trusted from the perspective of the Avast product. This bypasses the Self-Defense feature of the product, opening a door to subsequent attack on many of its components.
The bug was discovered 03/31/2017. The weakness was disclosed 04/27/2017 by Martin (Website). The advisory is available at trustwave.com. This vulnerability was named CVE-2017-8308 since 04/27/2017. Local access is required to approach this attack. A single authentication is necessary for exploitation. The technical details are unknown and an exploit is not available. This vulnerability is assigned to T1068 by the MITRE ATT&CK project.
The vulnerability was handled as a non-public zero-day exploit for at least 27 days. During that time the estimated underground price was around $5k-$25k.
Upgrading to version 17 eliminates this vulnerability.
The vulnerability is also documented in the vulnerability database at SecurityFocus (BID 98084†). The entry VDB-100641 is pretty similar. If you want to get best quality of vulnerability data, you may have to visit VulDB.
Product
Type
Vendor
Name
Version
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 6.4VulDB Meta Temp Score: 6.3
VulDB Base Score: 5.3
VulDB Temp Score: 5.1
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 7.5
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Access controlCWE: CWE-264
CAPEC: 🔍
ATT&CK: 🔍
Physical: Partially
Local: Yes
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
OpenVAS ID: 801111
OpenVAS Name: Avast Pro Antivirus Multiple Vulnerabilities
OpenVAS File: 🔍
OpenVAS Family: 🔍
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔍
Upgrade: Antivirus 17
Timeline
03/31/2017 🔍04/27/2017 🔍
04/27/2017 🔍
04/27/2017 🔍
04/27/2017 🔍
04/28/2017 🔍
12/21/2020 🔍
Sources
Advisory: trustwave.comResearcher: Martin Rakhmanov (Martin)
Status: Not defined
CVE: CVE-2017-8308 (🔍)
GCVE (CVE): GCVE-0-2017-8308
GCVE (VulDB): GCVE-100-100642
SecurityFocus: 98084 - Avast! Antivirus CVE-2017-8308 Security Bypass Vulnerability
OSVDB: - CVE-2017-8308 - Avast - Antivirus - Medium
See also: 🔍
Entry
Created: 04/28/2017 20:18Updated: 12/21/2020 16:13
Changes: 04/28/2017 20:18 (67), 09/21/2020 16:54 (4), 12/21/2020 16:13 (2)
Complete: 🔍
Cache ID: 216::103
If you want to get best quality of vulnerability data, you may have to visit VulDB.
No comments yet. Languages: en.
Please log in to comment.